Iterum Therapeutics provides business update

Iterum Therapeutics (ITRM) provided a business update. Payor Reimbursement and Contracting Expands with Major PBM Agreement: ORLYNVAH’s market access continues to accelerate. Iterum have finalized a commercial contract with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers in the United States, adding coverage opportunities for more than 40 million lives starting in early 2026. This milestone underscores. Beginning in Q1 2026, Iterum plans to launch targeted pull-through campaigns focused on prescribers in high-coverage geographies, while Iterum awaits approval of additional Commercial and Medicare Part D agreements currently pending execution. Expansion of Patent Estate: The Japanese Patent Office has issued a Decision to Grant in Japanese Patent Application No. 2022-554381, entitled “Combinations of Beta-Lactam Compounds, Probenecid, and Valproic Acid and Uses Thereof”. The allowed claims cover a combination of sulopenem etzadroxil, probenecid, and valproic acid for treating specified diseases. Upon issuance, this Japanese Patent will be projected to expire in March 2041, absent any extensions, and assuming timely payments of all maintenance fees during the lifetime of the patent.